CoChat
Sign Up
Cited by 87Autism Spectrum Disorder ResearchBehavioral and Psychological StudiesGenetics and Neurodevelopmental Disorders

A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism

Du, Lin, Shan, Ling, Wang, Bing, Li, Honghua, Xu, Zhida, Staal, Wouter G., Jia, Feiyong·2015·Journal of Child and Adolescent Psychopharmacology
DOI 10.1089/cap.2015.0045
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism. METHODS: Sixty children diagnosed with autism according to the International Classification of Diseases, Tenth Revision (ICD-10) criteria (mean age of 4.5 years) were randomly divided into two groups: A single treatment group (n=28) and a combined treatment group (n=32). The combined treatment group received ABA training combined with oral bumetanide (0.5 mg twice a day). The single treatment group received ABA training only. Autism symptoms were evaluated with the Autism Behavior Checklist (ABC) and the Childhood Autism Rating Scale (CARS), whereas severity of disease (SI) and global improvement (GI) were measured with the Clinical Global Impressions (CGI). Assessment of ABC, CARS, and CGI was performed immediately before and 3 months after initiation of the treatment(s). RESULTS: Prior to intervention(s) no statistically significant differences in scores on the ABC, CARS, SI, or GI were found between the two groups. Total scores of the ABC, CARS, and SI were decreased in both groups after 3 months (p<0.05) compared with the scores prior to treatment. The total scores of the ABC and the CGI were significantly (p<0.05) lower in the combined treatment group than in the single treatment group. Although the total and item scores of the CARS in the combined treatment group were lower than in the single treatment group after a 3 month intervention, they did not reach statistical significance. No adverse effects of bumetanide were observed. CONCLUSIONS: Treatment with bumetanide combined with ABA training may result in a better outcome in children with autism than ABA training alone.

Integrity signals

Registry

Crossref · 10.1089/cap.2015.0045

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Another study suggested possible combined effects of bumetanide with ABA therapy in improving ASD symptoms on the CARS, although it was not a randomized controlled trial.

    “Another study has suggested possible combined effects of bumetanide with ABA therapy in improving ASD symptoms on the CARS, although this was not a randomized controlled trial [98].”

    From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [98]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Du, L., Shan, L., Wang, B., Li, H., Xu, Z., Staal, W. G., & Jia, F.
Affiliations
  • First Hospital of Jilin University (CN)
  • University Medical Center Utrecht (NL)
  • Radboud University Medical Center (NL)
Corresponding author
Jia, Feiyong
ORCID
Venue
Journal of Child and Adolescent Psychopharmacology
Publisher
SAGE Publications
Published
2015-09
Volume
25
Issue
7
Pages
585-588
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
DOI
10.1089/cap.2015.0045
OpenAlex
W2465837042
Cited by
87
References
13
Citations by year
2026: 5 · 2025: 2 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 9 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 1
FWCI
3.01
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
autism spectrum disorder, applied behavior analysis, bumetanide, combination therapy, children, autism severity, autism pharmacotherapy
MeSH terms
Autistic Disorder, Behavior Therapy, Bumetanide, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Male, Pilot Projects, Psychiatric Status Rating Scales, Sodium Potassium Chloride Symporter Inhibitors, Checklist

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review